External guide sequence technology: A path to development of novel antimicrobial therapeutics

RNase P is a ribozyme originally identified for its role in maturation of tRNAs by cleavage of precursor tRNAs (pre-tRNAs) at the 5′-end termini. RNase P is a ribonucleoprotein consisting of a catalytic RNA molecule and, depending on the organism, one or more cofactor proteins. The site of cleavage...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Davies Sala, Carol G., Soler Bistué, Alfonso Juan de la Cruz, Zorreguieta, Angeles, Tolmasky, Marcelo Eduardo
Publicado:	2015
Materias:	Antimicrobials Antisense Drug design External guide sequence RNase P aminoglycoside 6' n acetyltransferase type Ib antibiotic agent bacterial enzyme FtsZ protein messenger RNA ribonuclease P unclassified drug antiinfective agent antisense oligonucleotide bacterial RNA ribozyme antibiotic resistance Article bacterial infection Brucella melitensis Cytomegalovirus enzyme inhibition Escherichia coli external guide sequence Francisella tularensis gene expression genetic procedures Hepatitis B virus human Human immunodeficiency virus Influenza virus nonhuman protein cleavage protein targeting Salmonella enterica serovar Typhimurium virus virus infection Yersinia pestis Bacterial Infections bacterium biological model chemistry conformation drug effects genetics metabolism microbiology Anti-Bacterial Agents Bacteria Humans Models, Genetic Nucleic Acid Conformation Oligoribonucleotides, Antisense Ribonuclease P RNA, Bacterial RNA, Catalytic
Acceso en línea:	https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00778923_v1354_n1_p98_DaviesSala http://hdl.handle.net/20.500.12110/paper_00778923_v1354_n1_p98_DaviesSala
Aporte de:	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

id	paper:paper_00778923_v1354_n1_p98_DaviesSala
record_format	dspace
spelling	paper:paper_00778923_v1354_n1_p98_DaviesSala2023-06-08T15:07:31Z External guide sequence technology: A path to development of novel antimicrobial therapeutics Davies Sala, Carol G. Soler Bistué, Alfonso Juan de la Cruz Zorreguieta, Angeles Tolmasky, Marcelo Eduardo Antimicrobials Antisense Drug design External guide sequence RNase P aminoglycoside 6' n acetyltransferase type Ib antibiotic agent bacterial enzyme FtsZ protein messenger RNA ribonuclease P unclassified drug antiinfective agent antisense oligonucleotide bacterial RNA ribozyme antibiotic resistance Article bacterial infection Brucella melitensis Cytomegalovirus enzyme inhibition Escherichia coli external guide sequence Francisella tularensis gene expression genetic procedures Hepatitis B virus human Human immunodeficiency virus Influenza virus nonhuman protein cleavage protein targeting Salmonella enterica serovar Typhimurium virus virus infection Yersinia pestis Bacterial Infections bacterium biological model chemistry conformation drug effects genetics metabolism microbiology Anti-Bacterial Agents Bacteria Bacterial Infections Humans Models, Genetic Nucleic Acid Conformation Oligoribonucleotides, Antisense Ribonuclease P RNA, Bacterial RNA, Catalytic RNase P is a ribozyme originally identified for its role in maturation of tRNAs by cleavage of precursor tRNAs (pre-tRNAs) at the 5′-end termini. RNase P is a ribonucleoprotein consisting of a catalytic RNA molecule and, depending on the organism, one or more cofactor proteins. The site of cleavage of a pre-tRNA is identified by its tertiary structure; and any RNA molecule can be cleaved by RNase P as long as the RNA forms a duplex that resembles the regional structure in the pre-tRNA. When the antisense sequence that forms the duplex with the strand that is subsequently cleaved by RNase P is in a separate molecule, it is called an external guide sequence (EGS). These fundamental observations are the basis for EGS technology, which consists of inhibiting gene expression by utilizing an EGS that elicits RNase P-mediated cleavage of a target mRNA molecule. EGS technology has been used to inhibit expression of a wide variety of genes, and may help development of novel treatments of diseases, including multidrug-resistant bacterial and viral infections. © 2015 The New York Academy of Sciences. Fil:Davies-Sala, C. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Fil:Soler-Bistué, A. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Fil:Zorreguieta, A. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Fil:Tolmasky, M.E. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. 2015 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00778923_v1354_n1_p98_DaviesSala http://hdl.handle.net/20.500.12110/paper_00778923_v1354_n1_p98_DaviesSala
institution	Universidad de Buenos Aires
institution_str	I-28
repository_str	R-134
collection	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic	Antimicrobials Antisense Drug design External guide sequence RNase P aminoglycoside 6' n acetyltransferase type Ib antibiotic agent bacterial enzyme FtsZ protein messenger RNA ribonuclease P unclassified drug antiinfective agent antisense oligonucleotide bacterial RNA ribozyme antibiotic resistance Article bacterial infection Brucella melitensis Cytomegalovirus enzyme inhibition Escherichia coli external guide sequence Francisella tularensis gene expression genetic procedures Hepatitis B virus human Human immunodeficiency virus Influenza virus nonhuman protein cleavage protein targeting Salmonella enterica serovar Typhimurium virus virus infection Yersinia pestis Bacterial Infections bacterium biological model chemistry conformation drug effects genetics metabolism microbiology Anti-Bacterial Agents Bacteria Bacterial Infections Humans Models, Genetic Nucleic Acid Conformation Oligoribonucleotides, Antisense Ribonuclease P RNA, Bacterial RNA, Catalytic
spellingShingle	Antimicrobials Antisense Drug design External guide sequence RNase P aminoglycoside 6' n acetyltransferase type Ib antibiotic agent bacterial enzyme FtsZ protein messenger RNA ribonuclease P unclassified drug antiinfective agent antisense oligonucleotide bacterial RNA ribozyme antibiotic resistance Article bacterial infection Brucella melitensis Cytomegalovirus enzyme inhibition Escherichia coli external guide sequence Francisella tularensis gene expression genetic procedures Hepatitis B virus human Human immunodeficiency virus Influenza virus nonhuman protein cleavage protein targeting Salmonella enterica serovar Typhimurium virus virus infection Yersinia pestis Bacterial Infections bacterium biological model chemistry conformation drug effects genetics metabolism microbiology Anti-Bacterial Agents Bacteria Bacterial Infections Humans Models, Genetic Nucleic Acid Conformation Oligoribonucleotides, Antisense Ribonuclease P RNA, Bacterial RNA, Catalytic Davies Sala, Carol G. Soler Bistué, Alfonso Juan de la Cruz Zorreguieta, Angeles Tolmasky, Marcelo Eduardo External guide sequence technology: A path to development of novel antimicrobial therapeutics
topic_facet	Antimicrobials Antisense Drug design External guide sequence RNase P aminoglycoside 6' n acetyltransferase type Ib antibiotic agent bacterial enzyme FtsZ protein messenger RNA ribonuclease P unclassified drug antiinfective agent antisense oligonucleotide bacterial RNA ribozyme antibiotic resistance Article bacterial infection Brucella melitensis Cytomegalovirus enzyme inhibition Escherichia coli external guide sequence Francisella tularensis gene expression genetic procedures Hepatitis B virus human Human immunodeficiency virus Influenza virus nonhuman protein cleavage protein targeting Salmonella enterica serovar Typhimurium virus virus infection Yersinia pestis Bacterial Infections bacterium biological model chemistry conformation drug effects genetics metabolism microbiology Anti-Bacterial Agents Bacteria Bacterial Infections Humans Models, Genetic Nucleic Acid Conformation Oligoribonucleotides, Antisense Ribonuclease P RNA, Bacterial RNA, Catalytic
description	RNase P is a ribozyme originally identified for its role in maturation of tRNAs by cleavage of precursor tRNAs (pre-tRNAs) at the 5′-end termini. RNase P is a ribonucleoprotein consisting of a catalytic RNA molecule and, depending on the organism, one or more cofactor proteins. The site of cleavage of a pre-tRNA is identified by its tertiary structure; and any RNA molecule can be cleaved by RNase P as long as the RNA forms a duplex that resembles the regional structure in the pre-tRNA. When the antisense sequence that forms the duplex with the strand that is subsequently cleaved by RNase P is in a separate molecule, it is called an external guide sequence (EGS). These fundamental observations are the basis for EGS technology, which consists of inhibiting gene expression by utilizing an EGS that elicits RNase P-mediated cleavage of a target mRNA molecule. EGS technology has been used to inhibit expression of a wide variety of genes, and may help development of novel treatments of diseases, including multidrug-resistant bacterial and viral infections. © 2015 The New York Academy of Sciences.
author	Davies Sala, Carol G. Soler Bistué, Alfonso Juan de la Cruz Zorreguieta, Angeles Tolmasky, Marcelo Eduardo
author_facet	Davies Sala, Carol G. Soler Bistué, Alfonso Juan de la Cruz Zorreguieta, Angeles Tolmasky, Marcelo Eduardo
author_sort	Davies Sala, Carol G.
title	External guide sequence technology: A path to development of novel antimicrobial therapeutics
title_short	External guide sequence technology: A path to development of novel antimicrobial therapeutics
title_full	External guide sequence technology: A path to development of novel antimicrobial therapeutics
title_fullStr	External guide sequence technology: A path to development of novel antimicrobial therapeutics
title_full_unstemmed	External guide sequence technology: A path to development of novel antimicrobial therapeutics
title_sort	external guide sequence technology: a path to development of novel antimicrobial therapeutics
publishDate	2015
url	https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00778923_v1354_n1_p98_DaviesSala http://hdl.handle.net/20.500.12110/paper_00778923_v1354_n1_p98_DaviesSala
work_keys_str_mv	AT daviessalacarolg externalguidesequencetechnologyapathtodevelopmentofnovelantimicrobialtherapeutics AT solerbistuealfonsojuandelacruz externalguidesequencetechnologyapathtodevelopmentofnovelantimicrobialtherapeutics AT zorreguietaangeles externalguidesequencetechnologyapathtodevelopmentofnovelantimicrobialtherapeutics AT tolmaskymarceloeduardo externalguidesequencetechnologyapathtodevelopmentofnovelantimicrobialtherapeutics
_version_	1768546390502277120

External guide sequence technology: A path to development of novel antimicrobial therapeutics

Ejemplares similares